Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Status:
Completed
Trial end date:
2021-01-19
Target enrollment:
Participant gender:
Summary
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex
for production of human IL-12. IL-12 is a protein that can improve the body's natural
response to disease by enhancing the ability of the immune system to kill tumor cells and may
interfere with blood flow to the tumor.
The main purpose of this study is to evaluate the safety and tolerability of a single
intratumoral injection of Ad-RTS-hIL-12 given with oral veledimex.